Real-world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: final analysis from a prospective observational cohort study (ENDEAVOUR)
Taylor, James Srirangan, Srinivasan Bukhari, Marwan Bilgrami, Syed Nisar, Muhammad K. McDonald, Stephen Goodson, Nicola Allard, Andrew Kinder, Alison Green, Michael
Taylor, James
Srirangan, Srinivasan
Bukhari, Marwan
Bilgrami, Syed
Nisar, Muhammad K.
McDonald, Stephen
Goodson, Nicola
Allard, Andrew
Kinder, Alison
Green, Michael
Abstract
Objective
Upadacitinib is recommended by National Institute for Health and Care Excellence in the UK in adults with moderate-to-severe rheumatoid arthritis (RA). This observational study assessed real-world clinical outcomes and patient-reported outcomes (PROs) in patients receiving upadacitinib for 6 months in the UK.
Methods
Patients from 14 centres in whom the decision to initiate upadacitinib had already been made were enrolled. Baseline data were retrospectively collected from patient records. Clinician-reported data were collected at routine clinic visits 3 and 6 months after upadacitinib initiation. Patient-reported data were collected directly from patients using an app (electronic PROs, ePROs). The primary end-point was proportion of patients achieving clinical remission (DAS28 CRP <2.6) after 6 months of upadacitinib.
Results
Data are available for 63 patients at all three datapoints and for 53 patients for the primary end-point. At 6 months, 40% (21/53) of patients achieved clinical remission and 21% (11/53) achieved low disease activity. Response was seen at 3 months for all efficacy end-points. ePROs allowed the capture of early patient-reported data which demonstrated clinically important improvements in pain and fatigue within 10 days and other PROs within 2 months. Improvements were also seen in metrics of activity, work and quality of life (QOL).
Conclusion
Patients in ENDEAVOUR showed similar early effectiveness with upadacitinib to that observed in clinical trials. Use of ePROs demonstrated rapid onset of action and meaningful improvements in QOL providing a potential opportunity to reduce outpatient visits for early responders, thus reducing the burden on rheumatology services.
MIDER Authors
Affiliations
Citations
Altmetric:
Date
2025
Type
Article
Collections
An error occurred retrieving the object's statistics
Citation
Taylor J, Srirangan S, Bukhari M, Bilgrami S, Nisar MK, McDonald S, Goodson N, Allard A, Kinder A, Green M, Hunt L, Raizada S, Kirkham B, Thomas E, Horsfall R, Niblock TL, Burton V, Galloway J. Real-world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: final analysis from a prospective observational cohort study (ENDEAVOUR). Curr Med Res Opin. 2025 Jun;41(6):1097-1109. doi: 10.1080/03007995.2025.2515280. Epub 2025 Jun 30